Research programme: P450RAI inhibitors - OPKO Health
Alternative Names: P450RAI inhibitors research programme - CytochromaLatest Information Update: 21 Apr 2014
At a glance
- Originator Cytochroma
- Class
- Mechanism of Action Cytochrome P-450 enzyme system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute promyelocytic leukaemia
Most Recent Events
- 04 Mar 2013 Cytochroma has been acquired by OPKO Health
- 17 Dec 2002 Discontinued - Preclinical for Acute promyelocytic leukaemia in Canada (unspecified route)
- 22 Sep 2000 A US patent has been issued to Cytochroma for Retinoid Metabolizing Protein